Znaczenie kliniczne i zastosowanie terapeutyczne melatoniny – obecny stan wiedzy

• Authors: Małgorzata Karbownik-Lewińska , Andrzej Lewiński

Title variants

EN

Clinical significance and therapeutic application of melatonin – current state of art

• Languages of publication: PL

Abstracts

PL

Melatonina jest czymś więcej niŜ jedynie hormonem i wiele jej działań wykracza poza ramy przydane hormonom, np. udział w szeregu reakcji oksydoredukcyjnych w charakterze potencjalnego zmiatacza wolnych rodników. W chwili obecnej istnieje kilka wskazań do stosowania terapeutycznego melatoniny u ludzi. Są to: 1) zaburzenia snu, zwłaszcza u osób w wieku podeszłym, 2) regulacja rytmu sen-czuwanie u osób niewidomych oraz u osób wykonujących pracę zmianową, 3) niwelowanie zaburzeń wynikających z szybkiej zmiany stref czasowych w czasie podróŜy międzykontynentalnych (jet-lag), 4) niektóre choroby psychiczne, w szczególności depresje. Dawka stosowanej melatoniny oraz długość kuracji powinny być zawsze dobierane indywidualnie i zaleŜeć od przyczyny jej stosowania. Przeciętne dawki stosowane w terapii wahają się od 1 do 5 mg. Występują obecnie silne tendencje, aŜeby melatoninę stosować w bardzo wielu chorobach i stanach klinicznych, w których działania melatoniny naukowo do końca nie wyjaśniono. Tym niemniej, autorzy donoszą zazwyczaj o pozytywnych wynikach terapii melatoniną, opierając tłumaczenie pozytywnego działania tego leku głównie na teorii wolnorodnikowej i udziale melatoniny w reakcjach oksydoredukcyjnych. Nie powinno się stosować melatoniny w okresie ciąŜy i karmienia i u zdrowych dzieci w kaŜdym wieku z powodu niepełnych badań na temat bezpieczeństwa stosowania. W oparciu o przesłanki teoretyczne zaleca się ostroŜność w stosowaniu melatoniny u osób z chorobami autoimmunologicznymi i alergicznymi.

EN

Melatonin is something more than merely a hormone and many of its actions exceed the frames, normally assigned to hormones, including, for example, involvement in numerous oxidoreductive reactions and the function of a potential scavenger of “free radicals”. At present, there are several approved indications for melatonin use in the therapy in humans: 1) sleep disorders, especially in advanced age, 2) regulation of sleep-wake circadian rhythms in the blind persons, and in case of shift-work disorders, 3) alleviation of jet-lag, 4) certain psychiatric diseases, in particular depressions. Dose of melatonin and duration of treatment should always be selected individually, and should depend on the cause of administration. The average therapeutic doses vary from l to 5 mg. There are also more and more frequent data on other therapeutic possibilities of this hormone. Strong trends are now observed toward melatonin recommendation in many diseases and clinical conditions, where, however, the mode and character of melatonin action are still far from the level of thorough understanding. Nevertheless, the authors usually report positive outcomes of melatonin administration, explaining the mechanism of observations mainly on the basis of the free-radical theory and on the participation of melatonin in oxidoreductive reactions. Melatonin should not be used by pregnant and lactating women, by healthy children of all ages, and by persons suffering from immune-system neoplasms. Melatonin should be used with caution by people with autoimmune and allergic diseases.

Keywords

EN

aging; agoniści melatoniny; choroby psychiczne; free radicals; jet-lag; melatonin; melatonin agonists; melatonin receptors; melatonina; neoplasms; nowotwory; proces starzenia; psychiatric diseases; receptory melatoninowe; sleep disorders; wolnerodniki; zaburzenia snu

Discipline

• MEDICINE: MEDICINE

• Publisher: Łódzkie Towarzystwo Naukowe
• Journal: Folia Medica Lodziensia
• Year: 2010
• Volume: 37
• Issue: 1
• Pages: 111-150

Contributors

author

Małgorzata Karbownik-Lewińska

• Klinika Endokrynologii i Chorób Metabolicznych, Uniwersytet Medyczny, Łódź, Klinika Endokrynologii i Chorób Metabolicznych, Instytut Centrum Zdrowia Matki Polki, Łódź

author

Andrzej Lewiński

• Zakład Endokrynologii Onkologicznej, Uniwersytet Medyczny, Łódź ,Klinika Endokrynologii i Chorób Metabolicznych, Instytut Centrum Zdrowia Matki Polki, Łódź

References

• Lerner AB, Case JD, Takahashi Y, Lee TH, Mori N. Isolation of melatonin, pineal factor that lightens melanocytes. J Am Chem Soc. 1958; 80:2587.
• Lerner AB, Case JD, Heinzelman RU. Structure of melatonin. J Am Chem Soc. 1959; 81:6084-6085.
• Dubocovich ML. Melatonin is a potent modulator of dopamine release in the retina. Nature. 1983; 306:782-784.
• Reppert SM, Weaver DR, Ebisawa T. Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron. 1994; 13:1177-1185.
• Arendt J. Melatonin and the mammalian pineal gland. Chapman and Hall, London, 1995.
• Vanhoutte PM, Humphrey PP, Spedding M. X. International Union of Pharmacology recommendations for nomenclature of new receptor subtypes. Pharmacol Rev. 1996; 48:1-2.
• Dubocovich ML. Cardinali DP, Guardiola-Lemaitre B, Hagan RM, Krause DN, Sugden D i wsp. Melatonin receptors. W: The IUPHAR Compendium of Receptor Characterization and Classification. IUPHAR Media, London, 1998: 187-193.
• Dubocovich ML. Cardinali DP, Delagrange P, Krause DN, Strosberg AD, Sugden D i wsp. Melatonin receptors. W: The IUPHAR Compendium of Receptor Characterization and Classification. Girdlestone D. (red.), wyd. 2, IUPHAR Media, London, 2000: 270-277.
• Dubocovich ML. Melatonin receptors: are there multiple subtypes? Trends Pharmacol Sci. 1995; 16:50-56.
• Molinari EJ, North PC, Dubocovich ML. 2-[125I]iodo-5-methoxycarbonylamino-N-acetyltryptamine: a selective radioligand for the characterization of melatonin ML2 binding sites. Eur J Pharmacol. 1996; 301:159-168.
• Nosjean O, Ferro M, Coge F, Beauverger P, Henlin JM, Lefoulon F i wsp. Identification of the melatonin binding site MT3 as quinine reductase 2. J Biol Chem. 2000; 275:31311-31317.
• Cogé F, Guenin SP, Fery I, Migaud M, Devavry S, Slugocki C i wsp. The end of a myth: cloning and characterization of the ovine melatonin MT2 receptor. Br J Pharmacol. 2009; 158:1248-1262.
• Dubocovich ML, Delagrange P, Krause DN, Sugden D, Cardinali DP, Olcese J. International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. Pharmacol Rev. 2010; 62:343-380.
• von Gall C, Garabette ML, Kell CA, Frenzel S, Dehghani F, Schumm-Draeger PM i wsp. Rhythmic gene expression in pituitary depends on heterologous sensitization by the neurohormone melatonin. Nat Neurosci. 2002; 5:234–238.
• Dubocovich ML, Hudson RL, Sumaya IC, Masana MI, Manna E. Effect of MT1 melatonin receptor deletion on melatonin-mediated phase shift of circadian rhythms in the C57BL/6 mouse. J Pineal Res. 2005; 39:113–120.
• Dubocovich ML. Melatonin receptors: role on sleep and circadian rhythm regulation. Sleep Med. 2007; 8: 34–42.
• Reppert SM, Godson C, Mahle CD, Weaver DR, Slaugenhaupt SA, Gusella JF. Molecular characterization of a second melatonin receptor expressed in human retina and brain: the Mel1b melatonin receptor. Proc Natl Acad Sci USA. 1995; 92:8734–8738.
• Dubocovich ML, Masana MI, Iacob S, Sauri DM. Melatonin receptor antagonists that differentiate between the human Mel1a and Mel1b recombinant subtypes are used to assess the pharmacological profile of the rabbit retina ML1 presynaptic heteroreceptor. Naunyn Schmiedebergs Arch Pharmacol. 1997; 355:365–375.
• Conway S, Drew JE, Mowat ES, Barrett P, Delagrange P, Morgan PJ. Chimeric melatonin MT1 and melatonin-related receptors. Identification of domains and residues participating in ligand binding and receptor activation of the melatonin MT1 receptor. J Biol Chem. 2000; 275:20602–20609.
• Audinot V, Mailliet F, Lahaye-Brasseur C, Bonnaud A, Le Gall A, Amossé C i wsp. New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn Schmiedebergs Arch Pharmacol. 2003; 367:553–561.
• Cajochen C, Kräuchi K, Möri D, Graw P, Wirz-Justice A. Melatonin and S-20098 increase REM sleep and wake-up propensity without modifying NREM sleep homeostasis. Am J Physiol. 1997; 272:R1189–R1196.
• Guilleminault C. P. 2.064 Efficacy of agomelatine versus venlafaxine on subjective sleep of patients with major depressive disorder. J Eur Coll Neuropsychophamacol. 2005; 15:S419–S420.
• Lôo H, Hale A, D’haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol. 2002; 17:239–247.
• Montgomery SA, Kennedy SH, Burrows GD, Lejoyeux M, Hindmarch I. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol. 2004; 19:271–280.
• Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman-Tancredi A, Pasteau V i wsp. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5 hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther. 2003; 306:954–964.
• Cajochen C. TAK-375 Takeda. Curr Opin Investig Drugs 2005; 6:114–121.
• Miyamoto M. Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders. CNS Neurosci Ther. 2009; 15:32–51.
• Meier PJ, Ziegler WH, Neftel K. [Benzodiazepine–practice and problems of its use.] Schweizerische medizinische Wochenschrift. 1988; 118:381–392.
• Mulchahey JJ, Goldwater DR, Zemlan FP. A single blind, placebo controlled, across groups dose escalation study of the safety, tolerability, pharmacokinetics and pharmacodynamics of the melatonin analog beta-methyl-6-chloromelatonin. Life Sci. 2004; 75:1843–1856
• Zemlan FP, Mulchahey JJ, Scharf MB, Mayleben DW, Rosenberg R, Lankford A. The efficacy and safety of the melatonin agonist beta-methyl-6-chloromelatonin in primary insomnia: a randomized, placebo-controlled, crossover clinical trial. J Clin Psych. 2005; 66:384–390.
• Leger D, Laudon M, Zisapel N. Nocturnal 6-sulfatoxymelatonin excretion in insomnia and its relation to the response to melatonin replacement therapy. Am J Med. 2004; 116:91–95.
• Garfinkel D, Laudon M, Zisapel N. Improvement of sleep quality by controlled-release melatonin in benzodiazepine-treated elderly insomniacs. Arch Gerontol Geriatr. 1997; 24:223–231.
• De Leersnyder H, Bresson JL, de Blois MC, Souberbielle JC, Mogenet A, Delhotal-Landes B i wsp. Beta 1-adrenergic antagonists and melatonin reset the clock and restore sleep in a circadian disorder, Smith-Magenis syndrome. J Med Genet. 2003; 40:74–78.
• Macchi MM, Bruce JN. Human pineal physiology and functional significance of melatonin. Front Neuroendocrinol. 2004; 25: 177-195.
• Blask DE, Sauer LA, Dauchy RT. Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr Top Med Chem. 2002; 2:113-132.
• Smirnov AN. Nuclear melatonin receptors. Biochemistry 2001; 66:19-26.
• Jung B, Ahmad N. melatonin in cancer management: progress and promise. Cancer Res. 2006; 66:9789-9793.
• García-Navarro A, González-Puga C, Escames G, López LC, López A, López-Cantarero M i wsp. Cellular mechanisms involved in the melatonin inhibition of HT-29 human colon cancer cell proliferation in culture. J Pineal Res. 2007; 43:195-205.
• García-Santos G, Antolín I, Herrera F, Martín V, Rodriguez-Blanco J, del Pilar Carrera M i wsp. Melatonin induces apoptosis in human neuroblastoma cancer cells. J Pineal Res. 2006; 41:130-135.
• Jawed S, Kim B, Ottenhof T, Brown G.M, Werstiuk ES, Niles LP. Human melatonin MT1 receptor induction by valproic acid and its effects in combination with melatonin on MCF-7 breast cancer cell proliferation. Eur J Pharmacol. 2007; 560:17-22.
• Ying SW, Niles LP, Crocker C. Human malignant melanoma cells express high affinity receptors for melatonin: antiproliferative effects of melatonin and 6 chloromelatonin. Eur J Pharmacol. 1993; 246:89-96.
• Xi SC, Tam PC, Brown GM, Pang SF, Shiu SY. Potential involvement of mt1 receptor and attenuated sex steroid-induced calcium influx in the direct antiproliferative action of melatonin on androgen-responsive LNCaP human prostate cancer cells. J Pineal Res. 2000; 29:172-183.
• Tam CW, Chan KW, Liu VW, Pang B. Melatonin as a negative mitogenic hormonal regulator of human prostate epithelial cell growth: potential mechanisms and clinical significance. J Pineal Res. 2008; 45:403-412.
• Watanabe M, Kobayashi Y, Takahashi N, Kiguchi K, Ishizuka B. Expression of melatonin receptor (MT1) and interaction between melatonin and estrogen in endometrial cancer cell line. J Obstet Gynaecol. 2008; 34:567-573.
• Cos S, Gonzalez A, Martinez-Campa C, Mediavilla MD, Alonso-Gonzalez C, Sanchez-Barcelo EJ. Melatonin as a selective estrogen enzyme modulator. Curr Cancer Targets. 2008; 8:691-702.
• Tan D-X, Chen LD, Poeggeler B, Manchester LC, Reiter RJ. Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocrine J. 1993; 1:57-60.
• Reiter RJ. Oxidative damage in the central nervous system: protection by melatonin. Progr Neurobiol. 1998; 56:359-384.
• Rodriguez C, Mayo JC, Sainz RM, Antolín I, Herrera F, Martín V i wsp. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res. 2004; 36:1-9.
• Sewerynek E, Poeggeler B, Melchiorri D, Reiter RJ. H2O2-induced lipid peroxidation in rat brain homogenates is greatly reduced by melatonin. Neurosci Lett. 1995; 195:203-205.
• Cabrera J, Burkhardt S, Tan DX, Manchester LC, Karbownik M, Reiter RJ. Autoxidation and toxicant-induced oxidation of lipid and DNA in monkey liver: reduction of molecular damage by melatonin. Pharmacol Toxicol. 2001; 89:225 230.
• Osuna C, Reiter RJ, García JJ, Karbownik M, Tan DX, Calvo JR i wsp. Inhibitory effect of melatonin on homocysteine-induced lipid peroxidation in rat brain homogenates. Pharmacol Toxicol. 2002; 90:32-37.
• Sewerynek E, Reiter RJ, Melchiorri D, Ortiz GG, Lewinski A. Oxidative damage in the liver induced by ischemia-reperfusion: protection by melatonin. Hepatogastroenterology. 1996; 43:898-905.
• Karbownik M, Reiter RJ. Antioxidative effects of melatonin in protection against cellular damage caused by ionizing radiation. Proc Soc Exp Biol Med. 2000; 225:9 22.
• Karbownik M, Lewinski A, Reiter RJ. Anticarcinogenic actions of melatonin which involve antioxidative processes: comparison with other antioxidants. Int J Biochem Cell Biol. 2001; 33:735-753.
• Karbownik M, Reiter RJ. Melatonin protects against oxidative stress caused by delta-aminolevulinic acid: implications for cancer reduction. Cancer Invest. 2002; 20:276-286.
• Karbownik-Lewińska M, Lewiński A. Protective effects of melatonin against oxidative damage to macromolecules caused by selected potential carcinogens. Folia Med Lodz. 2010; 37:57-67.
• Karbownik-Lewińska M, Stępniak J, Krawczyk J, Zasada K, Szosland J, Gesing A i wsp. External hydrogen peroxide is not indispensable for experimental induction of lipid peroxidation via Fenton reaction in porcine ovary homogenates. Neuroendocrinol Lett. 2010; 31:343-347.
• Karbownik M, Lewiński A. The role of oxidative stress in physiological and pathological processes in the thyroid gland; possible involvement in pineal-thyroid interactions. Neuroendocrinol Lett. 2003; 24:293-303.
• Karbownik M, Lewiński A. Melatonin reduces Fenton reaction-induced lipid peroxidation in porcine thyroid tissue. J Cell Biochem. 2003; 90:806-811.
• Karbownik M, Stasiak M, Zasada K, Zygmunt A, Lewiński A. Comparison of potential protective effects of melatonin, indole-3-propionic acid, and propylthiouracil against lipid peroxidation caused by potassium bromate in the thyroid gland. J Cell Biochem. 2005; 95:131-138.
• Gitto E, Karbownik M, Reiter RJ, Tan DX, Cuzzocrea S, Chiurazzi P i wsp. Effects of melatonin treatment in septic newborns. Pediatr Res. 2001; 50:756-760.
• Gitto E, Tan DX, Reiter RJ, Karbownik M, Manchester LC, Cuzzocrea S i wsp. Individual and synergistic antioxidative actions of melatonin: studies with vitamin E, vitamin C, glutathione and desferrioxamine (desferoxamine) in rat liver homogenates. J Pharm Pharmacol. 2001; 53: 1393-1401.
• Gitto E, Romeo C, Reiter RJ, Impellizzeri P, Pesce S, Basile M i wsp. Melatonin reduces oxidative stress in surgical neonates. Pediatr Surg. 2004; 39:184-189.
• Gitto E, Pellegrino S, Gitto P, Barberi I, Reiter RJ. Oxidative stress of the newborn in the pre- and postnatal period and the clinical utility of melatonin. J Pineal Res. 2009; 46:128-139.
• Bonnefont-Rousselot D, Collin F. Melatonin: Action as antioxidant and potential applications in human disease and aging. Toxicology. 2010, w druku.
• Reiter RJ. The pineal gland and its hormones in the control of reproduction in mammals. Endocr Rev. 1980; 1:109-131.
• Attanasio A, Ranke MB, Gupta D. Circadian rhythms in serum melatonin from infancy to aldolescence. J Clin Endocrinol Metab. 1985; 61:388-390.
• Arendt J. Melatonin assay in body fluids. J Neural Transm. 1978; 13 (Suppl.):265 278.
• Berge SL, Motola JF, Yen SCC. Amplification of nocturnal melatonin secretion in women with functional hypothalamic amenorrhea. J Clin Endocrinol Metab. 1988; 66:242-244.
• Laughlin GA, Louchs AB, Yen SCC. Marked augmentation of nocturnal melatonin secretion in amenorrheic athletes, but not in cyclic athletes: unaltered by opiodergic or dopaminergic blockade. J Clin Endocrinol Metab. 1991; 73:1321-1326.
• Arendt J, Bhanji S, Franey C, Mattingly D. Plasma melatonin levels in anorexia. Br J Psychiatry. 1992; 161:361-364.
• Puig-Domingo M, Webb SM, Serrano J, Peinado MA, Corcoy J, Ruscalleda J i wsp. Melatonin-related hypogonadotropic hypogonadism. New Engl J Med. 1992; 327:1356-1359.
• Karasek M, Pawlikowski M, Nowakowska-Jankiewicz B, Kołodziej-Maciejewska H, Zieleniewski J, Cieślak D i wsp. Circadian variations in plasma melatonin, FSH, LH, prolactin, and testosterone levels in infertile men. J Pineal Res. 1990; 9:149 157.
• Reiter RJ, Tan D-X, Manchester LC, Paredes SD, Mayo JC, Sainz RM. Melatonin and reproduction revisited. Biol Reprod. 2009; 81:445-456.
• Karasek M, Reiter RJ. The pineal gland and prolactin. Adv Pineal Res. 1990; 4:17 26.
• Attanasio A, Bombelli M, Kuzmanovic D, Gupta D. The pineal influence on growth hormone secretion. Neuroendocrinol Lett. 1986; 8:275-282.
• Karasek M, Stawerska R, Smyczyńska J, Lewiński A. Increased melatonin concentrations in children with growth hormone deficiency. J Pineal Res. 2007; 42:119-124.
• Maestroni GJM. The immunoneuroendocrine role of melatonin. J Pineal Res. 1993; 14:l-10.
• Reiter RJ, Robinson J. Melatonin. Bantam Books, New York, 1995.
• Lewiński A, Żelazowski P, Sewerynek E, Żerek-Mełeń G, Szkudliński M, Żelazowska E. Melatonin-induced suppression of human lymphocyte natural killer activity in vitro. J Pineal Res. 1989; 7:153-164.
• Lewiński A, Sewerynek E. Melatonin inhibits the basal and TSH-stimulated mitotic activity of thyroid follicular cells in vivo and in organ culture. J Pineal Res. 1986; 3:291-299.
• Lewiński A, Wajs E, Klencki M, Karbownik M, Gesing A, Sewerynek E i wsp. Pineal-thyroid interrelationships update: 1996. W: Pineal update from molecular mechanisms to clinical implications. Webb SM, Puig-Domingo M, Moller M, Pévet P. (red.), PJD Publ. Ltd., Westbury, New York, 1997: 173-181.
• Lewiński A, Karbownik M. Involvement of free radicals and reactive oxygen species in physiological and pathological processes in the thyroid gland; a potential role of melatonin. W: Melatonin: from molecules to therapy. Pandi-Perumal SR, Cardinali DP. (red.), Nova Science Publishers Inc., New York, 2007: 699-716.
• Kennaway DJ, Stamp GE, Goble FC. Development of melatonin production in infants and the impact of prematurity. J Clin Endocrinol Metab. 1992; 75:367-369.
• Waldhauser F, Kovacs J, Reiter E. Age-related changes in melatonin levels in humans and its potential consequences for sleep disorders. Exp Gerontol. 1998; 33:759-772.
• Pierpaoli W, Lesnikov V. Theoretical consideration on the nature of the pineal “ageing clock”. Gerontology. 1997; 43:20-25.
• Karasek M, Reiter RJ. Czy szyszynka odgrywa rolę w procesie starzenia? Endokrynol Pol - Pol J Endocrinol. 1997; 48:277-284.
• Benot S, Goberna R, Reiter RJ, Garcia Maurino E, Osuna C, Guerrero JM. Physiological levels of melatonin contribute to the antioxidant capacity of human serum. J Pineal Res. 1999; 27:59-64.
• Reiter RJ. Aging and oxygen toxicity: relation to changes in melatonin. Age. 1997; 20:201-213.
• Dmitriev LF, Titov VN. Lipid peroxidation in relation to ageing and the role of endogenous aldehydes in diabetes and other age-related diseases. Ageing Res Rev. 2010; 9:200-210.
• Reiter RJ, Paredes SD, Korkmaz A, Manchester LC, Tan DX. Melatonin in relation to the "strong" and "weak" versions of the free radical theory of aging. Adv Med Sci. 2008; 53:119-129.
• Thorpy MJ. Managing the patient with shift-work disorder. J Fam Pract. 2010; 59 (Suppl.):S24-31.
• Aeschbach D, Lockyer BJ, Dijk DJ, Lockley SW, Nuwayser ES, Nichols LD i wsp. Use of transdermal melatonin delivery to improve sleep maintenance during daytime. Clin Pharmacol Ther. 2009; 86:378-382.
• Zee PC, Wang-Weigand S, Wright KP Jr, Peng X, Roth T. Effects of ramelteon on insomnia symptoms induced by rapid, eastward travel. Sleep Med. 2010; 11:525-533.
• Zee PC, Goldstein CA. Treatment of shift work disorder and jet lag. Curr Treat Options Neurol. 2010; 12:396-411.
• Srinivasan V, Spence DW, Pandi-Perumal SR, Trakht I, Cardinali DP. Jet lag: therapeutic use of melatonin and possible application of melatonin analogs. Travel Med Infect Dis. 2008; 6:17-28.
• Srinivasan V, Singh J, Pandi-Perumal SR, Brown GM, Spence DW, Cardinali DP. Jet lag, circadian rhythm sleep disturbances, and depression: the role of melatonin and its analogs. Adv Ther 2010; DOI 10.1007/s12325-010-0065-y.
• Sack RL. Jet lag. New Eng J Med. 2010; 362:440-447.
• Sack RL. The pathophysiology of jet lag. Travel Med Infect Dis. 2009; 7:102-110.
• Brown GM, Pandi-Perumal SR, Trakht I, Cardinali DP. Melatonin and its relevance to jet lag. Travel Med Infect Dis. 2009; 7:69-81.
• Hirai K, Kita M, Ohta H, Nishikawa H, Fujiwara Y, Ohkawa S i wsp. Ramelteon (TAK-375) accelerates reentrainment of circadian rhythm after a phase advance of the light-dark cycle in rats. J Biol Rhythms. 2005; 20:27-37.
• Leproult R, Van Onderbergen A, L'hermite-Balériaux M, Van Cauter E, Copinschi G. Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men. Clin Endocrinol (Oxf). 2005; 63:298-304.
• Nickelsen T, Samel A, Vejvoda M, Wenzel J, Smith B, Gerzer R. Chronobiotic effects of the melatonin agonist LY 156735 following a simulated 9h time shift: results of a placebo-controlled trial. Chronobiol Int. 2002; 19:915-936.
• Rajaratnam SM, Polymeropoulos MH, Fisher DM, Roth T, Scott C, Birznieks G i wsp. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep time shift: two randomised controlled multicentre trials. Lancet. 2009; 373:482-491.
• Skene DJ, Lockley SW, Arendt J. Melatonin in circadian sleep disorders in the blind. Biol Signals Recept. 1999; 8:90-95.
• Pandi-Perumal SR, Trakht I, Spence DW, Srinivasan V, Dagan Y, Cardinali DP. The roles of melatonin and light in the pathophysiology and treatment of circadian rhythm sleep disorders. Nature Clin Pract Neurol. 2008; 4:436-447.
• Ferguson SA, Rajaratnam SM, Dawson D. Melatonin agonist and insomnia. Expert Rev Neurother. 2010; 10:305-318.
• Pandi-Perumal SR, Srinivasan V, Spence DW, Moscovitch A, Hardeland R, Brown GM i wsp. Ramelteon: a review of the therapeutic potential in sleep disorders. Adv Ther. 2009; 26:613-626.
• Gammack JK. Light therapy for insomnia in older adults. Clin Geriatr Med. 2008; 24:139-149.
• Sajith SG, Clarke D. Melatonin and sleep disorders associated with intellectual disability: a clinical review. J Intellect Dis Res. 2007; 51:2-13.
• McAlister-Williams RH, Baldwin DS, Haddad PM, Bazire S. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol Clin Exp. 2010; 25:95-102.
• San L, Arranz B. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. Eur Psychiatr. 2008; 23:396-402.
• Popoli M. Agomelatine. Innovative pharmacological approach in depression. CNS Drugs 2009; 23 (Suppl. 2):27-34.
• Kennedy SH. Agomelatine. Efficacy at each phase of antidepressant treatment. CNS Drugs 2009; 23 (Suppl. 2):41-47.
• Zarate CA, Manji HK. Bipolar disorder: candidate drug targets. Mount Sinai J Med. 2008; 75:226-247.
• Maldonado MD, Reiter RJ, Perez-San-Gregorio MA. Melatonin as a potential therapeutic agent in psychiatric illness. Hum Psychopharmacol Clin Exp. 2009; 24:391-400.
• Trbovic SM. Schizophrenia as a possible dysfunction of the suprachiasmatic nucleus. Med Hypotheses. 2010; 74:127-131.
• Bersani G, Mameli M, Garavini A, Pancheri P, Nordio M. Reduction of night/day difference in melatonin blood levels as a possible disease-related index in schizophrenia. Neuroendocrinol Lett. 2003; 24:181-184.
• Wulff K, Joyce E, Middleton B, Dijk DJ, Foster RG. The suitability of actigraphy, diary data, and urinary melatonin profiles for quantitative assessment of sleep disturbances in schizophrenia: a case report. Chronobiol Int. 2006; 23:485-495.
• Lauterbach EC, Victoroff J, Coburn KL, Shillcutt SD, Doonan SM, Mendez MF. Psychopharmacological neuroprotection in neurodegenerative disease: assessing the preclinical data. J Neuropsych Clin Neurosci. 2010; 22:8-18.
• Pacchierotti C, Iapichino S, Bossini L, Pieraccini F, Castrogiovanni P. Melatonin in psychiatric disorders: a review on the melatonin involvement in psychiatry. Front Neuroendocrinol. 2001; 22:18-32.
• Kennedy SH, Rizvi S. Sexual dysfunction, depression, and the impact of antidepressants. J Clin Psychopharmacol. 2009; 29:157-163.
• Brotto LA, Gorzalka BB, LaMarre AK. Melatonin protects against the effects of chronic stress on sexual behaviour in male rats. Neuroreport. 2001; 12:3465-3469.
• Altun A, Ugur-Altun B. melatonin: therapeutic and clinical utilization. Int J Clin Pract. 2007; 5:835-845.
• Pappola MA, Chyan YJ, Poeggeler B, Frangione B, Wilson G, Ghiso J i wsp. An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: implications for Alzheimer's disease. J Neural Transm. 2000; 107:203-231.
• Miller JW, Selhub J, Joseph JA. Oxidative damage caused by free radicals produced during catecholamine autooxidation: protective affect of O-methylation and melatonin. Free Radical Biol Med. 1996; 21:241-249.
• Adi N, Mash DC, Ali Y, Singer C, Shehadeh L, Papapetropoulos S. Melatonin MT1 and MT2 receptor expression in Parkinson's disease. Med Sci Monit. 2010; 16:BR61-67.
• Mehta BK. New hypotheses on sunlight and the geographic variability of multiple sclerosis prevalence. J Neurol Sci. 2010; 292:5-10.
• Lissoni P, Paolorossi F, Meregalli S, Ardizzoia A, Barni S, Tancini G. Melatonin as a modulator of cancer endocrine therapy. Front Horm Res. 1997; 23:132-136.
• Karasek M, Kuzdak K, Cywiński J, Żylińska K, Śmiałowska A, Plużańska A. Effects of melatonin administration in advanced breast cancer patients - preliminary report. Neuroendocrinol Lett. 1998; 19:15-19.
• Lissoni P, Barni S, Tancini G, Mainini E, Piglia F, Maestroni GJ i wsp. Immunoendocrine therapy with low-dose subcutaneous interleukin-2 plus melatonin of locally advanced or metastatic endocrine tumors. Oncology. 1995; 52:163-166.
• Simco F, Paulis L. Melatonin as a potential antihypertensive treatment. J Pineal Res. 2007; 42:319-322.
• Domingez-Rodriguez A, Abreu-Gonzalez A, Reiter RJ. Clinical aspects of melatonin in the acute coronary syndrome. Curr Vascular Pharmacol. 2009; 7:367-373.
• Korkmaz A, Topal T, Tan D-X, Reiter RJ. Role of melatonin in metabolic regulation. Rev Endocr Metab Disord. 2009; 10:261-270.
• Kalpakcioglu B, Senel K. The role of melatonin in rheumatic diseases. Infectious Dis – Drug Targets 2009; 9:453-456.
• Naguib M, Gottumukkala V, Goldstein PA. Melatonin and anesthesia: a clinical perspective. J Pineal Res. 2007; 42:12-21.
• Caumo W, Torres F, Moreira NL, Auzani JAS, Monteiro CA, Londero G i wsp. The clinical impact of preoperative melatonin on postoperative outcomes in patients undergoing abdominal hysterectomy. Anesth Analag. 2007; 105:1263-1271.
• Huang H, Yin R, Zhu J, Feng X, Wang C, Sheng Y i wsp. Exogenous melatonin ameliorates hepatic injury in a rat cardiopulmonary bypass model. Eur J Pharmacol. 2008; 580:416-428.
• Briceño-Pérres C, Briceño-Sanabria L, Vigil-De Gracia P. Prediction and prevention of preeclampsia. Hyperten Pregnancy. 2009; 28:138-155.
• Srinivasan V, Spence DW, Moscovitch A, Pandi-Perumal SR, Trakht I, Brown GM i wsp. Malaria: therapeutic implications of melatonin. J Pineal Res. 2010; 48:1-8.
• Gómez-Moreno G, Guardia J, Ferrera MJ, Cutando A, Reiter RJ. Melatonin in diseases of the oral cavity. Oral Dis. 2010; 16:242-247.
• Badgewell C, Rosen T. Cutaneous sarcoidosis therapy updated. J Am Acad Dermatol. 2007; 56:69-83.
• Fildes JE, Yonan N, Keevil BG. Melatonin – a pleiotropic molecule involved in pathophysiological processes following organ transplantation. Immunology. 2009; 127:443-449.
• Paredes SD, Korkmaz A, Manchester LC, Tan D-X, Reiter RJ. Phytomelatonin: a review. J Exp Botany. 2009; 60:57-69.
• Barchas J, DaCosta F, Spector S. Acute pharmacology of melatonin. Nature. 1967; 214:919-920.
• Karasek M, Lewiński A, Reiter RJ. Melatonina: znaczenie kliniczne i zastosowanie terapeutyczne. Endokrynol Pol – Pol J Endocrinol. 2001; 52:81-100.
• Pawlikowski M, Winczyk K, Karasek M. Oncostatic action of melatonin: facts and question marks. Neuroendocrinol Lett 2002; 23(Suppl. 1):24-29.
• Karasek M, Winczyk K. Melatonin in humans. J Physiol Pharmacol 2006; 57(Suppl. 5):19-39.

• Document Type: paper